Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats

Carcinogenesis

Volumn 17, Issue 2, 1996, Pages 373-376

  Pereira, Michael A ^a,b   Barnes, Leta H ^a   Steele, Vernon E ^c   Kelloff, Gary V ^c   Lubet, Ronald A ^c  

^a Environmental Health Research and Testing   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; PIROXICAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER REGRESSION; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; INTESTINE CRYPT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRECANCER; PRIORITY JOURNAL; RAT;

ADENOCARCINOMA; ADENOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZOXYMETHANE; CARCINOGENS; COLON; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; MALE; PIROXICAM; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344;

EID: 0029927003     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.2.373     Document Type: Article

References (22)

1. Boring, C.C., Squires, T.S. and Tong, T. (1993) Cancer facts and figures. CA Cancer J. Clin., 43, 7-26.
2. Reddy, B.S., Rao, C.V., Rivenson, A. and Kelloff, G.J. (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-1497.
3. Reddy, B.S., Maruyama, H. and Kelloff, G. (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47, 5340-5346.
4. Metzger, U., Meier, J., Uhlschmid, G. and Weihe, H. (1984) Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis. Colon Rectum, 27, 366-369.
5. Moorghen, M., Ince, P., Finney, K.J., Sunter, J.P., Appleton, D.R. and Watson, A.J.A. (1988) A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J. Pathol., 156, 341-347.
6. Marnett, L.J. (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52, 5575-5589.
7. Rosenberg, L., Parmer, J.R., Zauber, A.G., Warshauer, M.E., Stolley, P.D. and Shapiro, S. (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl Cancer Inst., 83, 355-358.
8. Paganini-Hill, A., Hsu, G., Ross, R.K. and Henderson, B.E. (1991) Aspirin use and incidence of large-bowel cancer in a California retirement community. J. Natl Cancer Inst., 83, 1182-1183.
9. Rao, C.V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V. and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55, 1464-1472.
10. Laybayle, D., Fischer, D., Viehl, P., Frouhin, F., Pariente, A., Bories, C., Duhamael, O., Trousset, M. and Atti, P. (1991) Sulindac causes regression of rectal polyps in familial adenomatosis polyposis. Gastroenterology, 101, 635-639.
11. Spagnesi, M.T., Tonelli, F., Dolara, P., Caderni, G., Valanzano, R., Anastasi, A. and Bianchini, F. (1994) Rectal proliferation and polyp occurrence in patients with familial adenomatosis polyposis after sulindac treatment. Gastroenterology, 106, 362-366.
12. Winde, G., Gumbinger, H.G., Osswald, H., Kemper, F. and Bunte, H. (1993) The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatosis polyposis: clinical results of a dose finding study on rectal sulindac administration. Int. J. Colorectal Dis., 8, 13-17.
13. Giardello, F.M., Hamilton, S.R., Krush, A.J., Piantodosi, S., Hylind, L.M., Cleano, P., Booker, S.V., Robinson, R.C. and Offerhaus, G.J.A. (1993) Treatment of colonic rectal adenomas with sulindac in familial adenomatosis polyposis. New Engl. J. Med., 328, 1313-1316.
14. Bird, R.P. (1987) Observations and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett., 37, 147-151.
15. McLellan, E.A., Medline, A. and Bird, R.P. (1991) Sequential analysis of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res., 51, 5270-5274.
16. Pretlow, R.P., O'Riordan, M.A., Koilman, M.F. and Jurcisek, J.A. (1990) Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity. Am. J. Pathol., 136, 13-16.
17. Pretlow, T.P., O'Roirdan, M.A., Spancake, K.M. and Pretlow, T.G. (1993) Two types of putative preneoplastic lesions identified in whole-mounts of colon from F344 rats treated with carcinogen. Am. J. Pathol., 142, 1695-1700.
18. Pereira, M.A., Barnes, L.H., Rassman, V.L., Kelloff, G.V. and Steele, V.E. (1994) Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis, 15, 1049-1054.
19. Pretlow, T.P., O'Riordan, M.A., Somich, G.A., Amini, S.B. and Pretlow, T.G. (1992) Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis, 13, 1509-1512.
20. McLellan, E.A., Medline, A. and Bird, R.P. (1991) Dose-response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis, 12, 2093-2098.
21. Bird, R.P. (1995) Further investigation of the effect of cholic acid on the induction, growth characteristics and stability of aberrant crypt foci in rat colon. Cancer Lett., 88, 202-209.
22. Bird, R.P. (1995) Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett., 93, 55-71.